Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Inventory (2017 - 2025)

Organogenesis Holdings (ORGO) has 8 years of Inventory data on record, last reported at $29.6 million in Q4 2025.

  • For Q4 2025, Inventory rose 13.0% year-over-year to $29.6 million; the TTM value through Dec 2025 reached $29.6 million, up 13.0%, while the annual FY2025 figure was $29.6 million, 13.0% up from the prior year.
  • Inventory reached $29.6 million in Q4 2025 per ORGO's latest filing, down from $39.6 million in the prior quarter.
  • Across five years, Inventory topped out at $39.6 million in Q3 2025 and bottomed at $22.7 million in Q1 2022.
  • Average Inventory over 5 years is $27.7 million, with a median of $27.4 million recorded in 2024.
  • Peak YoY movement for Inventory: decreased 23.5% in 2022, then skyrocketed 46.41% in 2025.
  • A 5-year view of Inventory shows it stood at $25.0 million in 2021, then dropped by 0.96% to $24.8 million in 2022, then rose by 14.0% to $28.3 million in 2023, then dropped by 7.2% to $26.2 million in 2024, then increased by 13.0% to $29.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $29.6 million in Q4 2025, $39.6 million in Q3 2025, and $33.0 million in Q2 2025.